Innovative Medicines Initiative

Source: Wikipedia, the free encyclopedia.

Innovative Medicines Initiative
Joint Technology Initiative on Innovative Medicines
Joint Technology Initiative (JTI)
Funding agencyEuropean Commission
FP7
ObjectiveRe-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development (R&D) investment in this sector
Budget
  • Total: 2 billion EUR
  • Funding: 1 billion EUR
Duration2008 – 2017
Websitewww.imi.europa.eu

The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the

Joint Technology Initiative within the Seventh Framework Programme.[1][2][3][4][5][6][7][8] Michel Goldman was the first executive director, from September 2009 until December 2014.[9]

The Innovative Medicines Initiative is aimed towards removing research

bottlenecks in the current drug development
process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.

The funding scheme has been criticised,[10] requiring universities to invest more money than with EU FP7 programs. Besides the non-competitive financial aspects of participation in IMI projects for academia, this criticism also discusses that intellectual property is freely flowing to industry.

The Sixth Framework Programme's research projects InnoMed AddNeuroMed and InnoMed PredTox acted as pilot projects establishing the feasibility of this particular public-private partnership.[11] Since then, the IMI has had four funding rounds: the first call had the topic Safety, while the second call was about Efficacy. Projects for these two calls are ongoing.[12]

The IMI 2 started in 2014 and will run until 2024, while the IMI 1 is still running. Overall budget is €3.276 billion, taken for half from the European

Horizon 2020
program. Goals of that second calls are to improve clinical trials success rate, deliver clinical proof of concept, biomarkers and new medicines.

IMI-Train

In September 2014 IMI-TRAIN, an IMI/ENSO-funded education and training collaboration to support biomedical scientists and professionals, has been launched. IMI-TRAIN will serve as a collaboration platform for the currently IMI-funded education and training projects:[13]

  • EMTRAIN: European Medicines Research Training Network
  • Eu2P: European programme in Pharmacovigilance and Pharmacoepidemiology
  • Pharmatrain: Pharmaceutical Medicine Training Programme
  • SafeSciMET: Safety Sciences Modular Education and Training

See also

References

  1. PMID 18256603
    .
  2. S2CID 11860265
    .
  3. PMID 22333557
    .
  4. S2CID 34263113
    .
  5. PMID 21106547
    .
  6. PMID 19383340
    .
  7. PMID 18448501
    .
  8. PMID 17611733
    .
  9. ^ "Professor Michel Goldman, Innovative Medicines Initiative". research-europe.com. Archived from the original on 20 May 2015. Retrieved 1 June 2015.
  10. PMID 21654659
    .
  11. ^ Reference on EFPIA's IMI site Archived 6 August 2008 at the Wayback Machine
  12. ^ Factsheets for IMI projects, IMI, 2011, retrieved 17 August 2011.
  13. ^ launch announcement September 2014 (Press Release)

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Innovative_Medicines_Initiative&oldid=1197226964"